Advisory Panel Backs Broad Boceprevir Label, But With Discussion Of Drug's Data Limitations
This article was originally published in The Pink Sheet Daily
Executive Summary
Members want physicians to make the decision on use for individual Hepatitis C patients despite lack of data on prior null responders.